Summary of Charles River Laboratories International (CRL) Conference Call Company Overview - **Company**: Charles River Laboratories International (CRL) - **Event**: 2025 Conference Call - **Date**: May 14, 2025 Key Points Financial Performance - CRL reported better-than-expected Q1 results, primarily driven by the DSA division [4][5] - Revenue outlook improved by 1% to a range of -4.5% to -2.5% for the year, with EPS guidance raised by $0.20 to a range of $9.3 to $9.8 [5] - Net book-to-bill ratio exceeded one for the first time in two years, indicating a positive trend in bookings [4][8] Booking Trends - Bookings increased by 20% year-over-year, mainly from global biopharma clients [9] - Short-term bookings were prevalent, indicating clients are moving forward with programs quickly [11][12] - Mid-tier biotech clients showed revenue growth, reflecting improved funding conditions [10] FDA Policy Impact - The FDA announced plans to reduce animal testing, which has implications for CRL's business model [5][15] - CRL has invested approximately $200 million in alternative methods and technologies to align with the FDA's new guidelines [18][19] - Current revenues from new approach methods (NAMS) are about $200 million annually, expected to grow as new technologies are validated [20] Manufacturing and CDMO Segment - The CDMO segment experienced a revenue decline due to the loss of a commercial client, impacting revenue by 500 basis points [32] - Despite this, there is a strong pipeline of interest from new clients, particularly in gene therapy [33][34] Research Models and Services (RMS) - RMS division has maintained pricing power despite a decline in animal usage, with a positive mix of more complex models [37] - Academic and government clients, which represent about 20% of RMS, have shown growth in Q1, with no immediate impact from NIH cuts [39][40] Non-Human Primate (NHP) Supply Chain - Concerns regarding NHP trade restrictions from Cambodia have been addressed, with CRL confident in its diversified supply chain [46][48] - Less than 30% of NHP supply comes from Cambodia, with efforts to increase capacity from Mauritius [48] Cost Savings and Efficiency - CRL aims for $175 million in annualized cost savings in 2025, increasing to $225 million in 2026 [51] - Focus areas include site consolidation and automation to improve efficiency [52][54] Market Outlook and Strategic Focus - No immediate changes in client priorities due to drug pricing policies; clients are focused on executing existing plans [56] - Potential for M&A exists, but current capital deployment is focused on share repurchases and debt repayment [60][61] Misunderstandings About CRL - CRL is primarily a drug development company, utilizing both in vivo and in vitro methods, and is committed to guiding regulatory agencies towards new technologies [63][64] Additional Insights - The transition to NAMS technologies will take time, with a focus on patient safety and scientific validation [22][28] - The company is well-positioned to adapt to changes in the regulatory landscape and market demands [22][46]

Core Viewpoint - Elliott Investment Management has entered into a cooperation agreement with Charles River Laboratories, leading to significant changes in the board of directors and a strategic review aimed at enhancing shareholder value [2][5]. Company Overview - Charles River Laboratories supports early-stage drug research and development, operating through three segments: Research Models and Services (20.48% of revenue), Discovery and Safety Assessment (60.52%), and Manufacturing Solutions (19.00%) [3]. - The company is a leader in pre-clinical development, holding a market share of 35% to over 40% in each segment, which is generally twice the size of the second-largest competitor [3]. Recent Challenges - Post-pandemic, there has been a pullback in pre-clinical research demand, leading to a decrease in funding and a reevaluation of pipelines by large pharmaceutical companies, negatively impacting Charles River and the sector [4]. - The company's shares have declined significantly, down 50.95%, 52.30%, and 19.66% over the past 1-, 3-, and 5-year periods, respectively [4]. Strategic Review and Value Creation - The strategic review initiated by Elliott aims to explore various avenues for creating shareholder value, including evaluating the Manufacturing Solutions business, which has grown revenue organically by over 10% annually for 20 years [7]. - A potential sale of the Manufacturing Solutions segment could yield a valuation of approximately half of Charles River's current market cap, despite representing only 20% of the company's earning power [7]. - The board may also consider acquiring smaller competitors, leveraging Elliott's expertise in conducting value-accretive mergers and acquisitions [8]. Potential for Acquisition - There is a possibility of exploring a sale of the entire company, given its critical role in drug development and high cash flow generation, making it appealing to potential financial acquirers [9]. - Elliott, as the largest shareholder with at least 12.5% ownership, has the capability to acquire the company if necessary changes are not made in the public market [9].

Charles River Laboratories (CRL) reported $984.17 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 2.7%. EPS of $2.34 for the same period compares to $2.27 a year ago.The reported revenue represents a surprise of +5.25% over the Zacks Consensus Estimate of $935.05 million. With the consensus EPS estimate being $2.06, the EPS surprise was +13.59%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectatio ...

Charles River Laboratories International, Inc. (CRL) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.34, which rose 3.1% year over year. The figure surpassed the Zacks Consensus Estimate by 13.6%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar). On a GAAP basis, the company reported earnings of 50 cents per share compared with the year-ago quarter's EPS of $1.31. CRL's Q1 Revenues Revenues totaled $984.2 million, which beat the Zacks Consensus Estimate by 5.2%. H ...

Charles River Laboratories International (CRL) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Company Participants Todd Spencer - Vice President, Investor RelationsJames Foster - Chairman, President and CEOFlavia Pease - Corporate Executive VP & CFOElizabeth Anderson - Senior Managing DirectorDave Windley - Managing DirectorMichael Ryskin - Managing DirectorKyle Crews - Equity Research AssociatePatrick Donnelly - Managing DirectorCasey Woodring - Vice President - Equity ResearchCharles Rhyee - Managing Dire ...

Charles River Laboratories International (CRL) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories First Quarter twenty twenty five Earnings Conference Call. This call is being recorded. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. I would now like to turn the conference over to our host, Todd Spencer, Vice President of ...

Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.59%. A quarter ago, it was expected that this medical research equipment and services provider would post earnings of $2.50 per share when it actually produced earnings of $2.66, delivering a surprise ...

Charles River Laboratories 1Q 2025 Results May 7, 2025 © 2025 Charles River Laboratories International, Inc. Safe Harbor Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that p ...

Exhibit 99.1 – First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – WILMINGTON, MA, May 7, 2025 – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. Th ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Charles River Laboratories (CRL) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on M ...